Compare Citius Pharmaceuticals Inc (CTXR) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Quanta Services Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $21.25M), while Quanta Services Inc trades at $672.59 (market cap $101.94B). The key difference: Quanta Services Inc is far larger — about 4797.2× Citius Pharmaceuticals Inc's market cap, and Quanta Services Inc pays a 0.06% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | PWR | |
|---|---|---|
Market Cap | $21.25M | $101.94B |
Sector | Health | Industrials |
52-Week High | $1.82 | $785.24 |
52-Week Low | $0.48 | $372.50 |
Enterprise Value | $17.47M | $108.03B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.765, up 6.25% today, with a bullish technical signal from moving averages. The company reported a net income margin of -823.34% for 2025 and missed EPS estimates in recent quarters. Recent news highlights strong commercial momentum for LYMPHIR, with Q2 2026 revenue of $5.6 million and expanded payer coverage.
The outlook is mixed: analyst consensus is strongly bullish (83% buy ratings), but fundamental risks are high due to persistent losses and cash burn. Upside depends on LYMPHIR's commercial success, while downside risks include funding needs and competitive pressures in oncology.
PWR trades at $672.78, up 0.33% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $28.48B in 2025, and the company raised its 2026 outlook, supported by record backlog and infrastructure demand. Analyst consensus is strongly bullish with a $809.75 price target.
The outlook is positive due to accelerating growth and raised guidance, but high valuation multiples (P/E 77.58) pose a risk. Key opportunities include AI-driven R&D expansion and power infrastructure projects, while execution delays and macroeconomic pressures are primary concerns for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
